These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16719813)

  • 1. Tricyclic quinoxalinediones, aza-kynurenic acids, and indole-2-carboxylic acids as in vivo active NMDA-glycine antagonists.
    Nagata R; Katayama S; Ohtani K; Tanaka H; Shimago K
    Curr Top Med Chem; 2006; 6(7):733-45. PubMed ID: 16719813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antagonistic activities of SM-31900 for the NMDA receptor glycine-binding site.
    Ohtani K; Tanaka H; Yoneda Y; Yasuda H; Ito A; Nagata R; Nakamura M
    Brain Res; 2002 Jul; 944(1-2):165-73. PubMed ID: 12106676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic indole-2-carboxylic acids: highly in vivo active and selective antagonists for the glycine binding site of the NMDA receptor.
    Katayama S; Ae N; Kodo T; Masumoto S; Hourai S; Tamamura C; Tanaka H; Nagata R
    J Med Chem; 2003 Feb; 46(5):691-701. PubMed ID: 12593650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity.
    Bigge CF; Malone TC; Boxer PA; Nelson CB; Ortwine DF; Schelkun RM; Retz DM; Lescosky LJ; Borosky SA; Vartanian MG
    J Med Chem; 1995 Sep; 38(19):3720-40. PubMed ID: 7562904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of tricyclic indole-2-carboxylic [correction of caboxylic] acids as potent NMDA-glycine antagonists.
    Katayama S; Ae N; Nagata R
    J Org Chem; 2001 May; 66(10):3474-83. PubMed ID: 11348132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites.
    Woodward RM; Huettner JE; Guastella J; Keana JF; Weber E
    Mol Pharmacol; 1995 Mar; 47(3):568-81. PubMed ID: 7700254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the novel tricyclic quinoxalinedione derivatives, SM-18400 and its analogs, on N-methyl-D-aspartate (NMDA) receptor-mediated synaptic transmission in the isolated neonatal rat spinal cord in vitro.
    Maruoka Y; Ohno Y; Tanaka H; Yasuda H; Otani K; Tamamura C; Nakamura M
    Jpn J Pharmacol; 1998 Mar; 76(3):265-70. PubMed ID: 9593219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDA receptor.
    Cai SX; Kher SM; Zhou ZL; Ilyin V; Espitia SA; Tran M; Hawkinson JE; Woodward RM; Weber E; Keana JF
    J Med Chem; 1997 Feb; 40(5):730-8. PubMed ID: 9057859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of a set of ethyl 1-carbamoyl-3-oxoquinoxaline-2-carboxylates and of their constrained analogue imidazo.
    Varano F; Catarzi D; Colotta V; Cecchi L; Filacchioni G; Galli A; Costagli C
    Eur J Med Chem; 2001 Feb; 36(2):203-9. PubMed ID: 11311751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors.
    Keana JF; Kher SM; Cai SX; Dinsmore CM; Glenn AG; Guastella J; Huang JC; Ilyin V; Lü Y; Mouser PL
    J Med Chem; 1995 Oct; 38(22):4367-79. PubMed ID: 7473565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel (Acea 1021) as NMDA/glycine site antagonists.
    Zhou ZL; Kher SM; Cai SX; Whittemore ER; Espitia SA; Hawkinson JE; Tran M; Woodward RM; Weber E; Keana JF
    Bioorg Med Chem; 2003 Apr; 11(8):1769-80. PubMed ID: 12659763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (E)-3-(2-(N-phenylcarbamoyl)vinyl)pyrrole-2-carboxylic acid derivatives. A novel class of glycine site antagonists.
    Balsamini C; Bedini A; Diamantini G; Spadoni G; Tontini A; Tarzia G; Di Fabio R; Feriani A; Reggiani A; Tedesco G; Valigi R
    J Med Chem; 1998 Mar; 41(6):808-20. PubMed ID: 9526557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tricyclic quinoxalinediones: 5,6-dihydro-1H-pyrrolo[1,2,3-de] quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de] quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor.
    Nagata R; Tanno N; Kodo T; Ae N; Yamaguchi H; Nishimura T; Antoku F; Tatsuno T; Kato T; Tanaka Y
    J Med Chem; 1994 Nov; 37(23):3956-68. PubMed ID: 7966156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UK-315716/UK-240455. Pfizer.
    Capelli AM; Micheli F
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1737-9. PubMed ID: 11892937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2-carboxyvinyl]-4,6-dichloro-1H-indole-2-carboxylic acid, a potent selective glycine-site NMDA receptor antagonist.
    Baron BM; Cregge RJ; Farr RA; Friedrich D; Gross RS; Harrison BL; Janowick DA; Matthews D; McCloskey TC; Meikrantz S; Nyce PL; Vaz R; Metz WA
    J Med Chem; 2005 Feb; 48(4):995-1018. PubMed ID: 15715469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia.
    Di Fabio R; Conti N; De Magistris E; Feriani A; Provera S; Sabbatini FM; Reggiani A; Rovatti L; Barnaby RJ
    J Med Chem; 1999 Sep; 42(18):3486-93. PubMed ID: 10479281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on N-methyl-D-aspartate receptors.
    Kleckner NW; Dingledine R
    Mol Pharmacol; 1989 Sep; 36(3):430-6. PubMed ID: 2550776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles.
    Kehne JH; Baron BM; Harrison BL; McCloskey TC; Palfreyman MG; Poirot M; Salituro FG; Siegel BW; Slone AL; Van Giersbergen PL
    Eur J Pharmacol; 1995 Sep; 284(1-2):109-18. PubMed ID: 8549613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycine/NMDA receptor antagonists as potential CNS therapeutic agents: ACEA-1021 and related compounds.
    Cai SX
    Curr Top Med Chem; 2006; 6(7):651-62. PubMed ID: 16719807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations of acidic functions at position 2 and substituents at positions 4, 5 and 6 of the indole moiety and their effect on NMDA-glycine site affinity.
    Jansen M; Dannhardt G
    Eur J Med Chem; 2003 Oct; 38(10):855-65. PubMed ID: 14575932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.